8/2/2020 8:44:03 PM
VistaGen Therapeutics Prices Underwritten Public Offering Of 15.63 Mln Shares At $0.80/shr
7/23/2020 8:11:37 AM
VistaGen Therapeutics Announces Positive Meeting With FDA Regarding Pivotal Phase 3 Study Of PH94B
5/27/2020 8:02:49 AM
VistaGen And Nuformix Announce Agreement To Develop Novel Patentable Cocrystalline Forms Of AV-101
5/18/2020 8:07:23 AM
VistaGen Submits PH94B Phase 2A Study Protocol For Treatment Of Adjustment Disorder With Anxiety On COVID-19 Pandemic
4/28/2020 9:16:43 AM
VistaGen Plans To Expand Clinical Development Of PH94B To Include Adjustment Disorder Related To COVID-19
3/25/2020 9:07:16 AM
VistaGen Therapeutics Enters Common Stock Purchase Agreement For Up To $10.25 Mln
2/20/2020 8:31:35 AM
VistaGen Announces Positive Results Of Newly Published Exploratory Phase 2a Study Of PH10
2/11/2020 8:33:25 AM
VistaGen Reports Positive Data Of AV-101 Combined With Probenecid Suggesting Increased Brain Concentration Effects
1/30/2020 8:32:29 AM
VistaGen Therapeutics Gets FDA Clearance Of IND For Phase 2 Clinical Study Of AV-101
12/10/2019 8:34:33 AM
FDA Grants VistaGen Therapeutics Fast Track Designation For PH94B For Treatment Of Social Anxiety Disorder
11/14/2019 7:33:24 AM
VistaGen Announces Disappointng Topline Phase 2 Results For AV-101
11/7/2019 6:44:13 AM
VistaGen Therapeutics Q2 Net Loss Attributable To Common Stockholders Narrows To $5.7 Mln From $7.7 Mln Last Year
10/28/2019 8:35:25 AM
VistaGen Therapeutics Expands European Patent Protection For AV-101 For Treatment Of Depression And Dyskinesia